Exclusive

Exclusive By Matthew Herper and Damian Garde

Raging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing

Exclusive By Ed Silverman

STAT-Harris Poll: Most Americans won’t get a Covid-19 vaccine unless it cuts risk by half

Exclusive By Ed Silverman

STAT-Harris Poll: The share of Americans interested in getting Covid-19 vaccine as soon as possible is dropping

Special Report By Lev Facher

First-of-its-kind examination shows how widely pharma showers campaign cash at the state level

Exclusive By Alison Insinger

Top health official echoes Trump’s Covid-19 views, drawing accusations of politicizing U.S. mental health agency

Exclusive By Rebecca Robbins, Adam Feuerstein, and Helen Branswell

AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.

Exclusive By Nicholas Florko and Lev Facher

PhRMA scrambles to respond to Trump’s drug pricing ultimatum, as Monday deadline looms

Exclusive By Helen Branswell, Kate Sheridan, Casey Ross, and Andrew Joseph

The Trump administration haphazardly gave away millions of Covid-19 masks — to schools, broadcasters, and large corporations

Exclusive By Nicholas Florko

FDA’s reopening plan will keep biologics labs shuttered far longer than other government labs

Exclusive By Erin Brodwin

Eyeing an IPO, Hims expands further into virtual mental health care

Exclusive By Nicholas Florko

In unusual arrangement, deputy HHS secretary’s wife has been lobbying the agency on behalf of health care companies

Exclusive By Matthew Herper and Erin Riglin

Data show panic and disorganization dominate the study of Covid-19 drugs

Exclusive By Ed Silverman

Pharma giants to unveil major $1 billion venture to push novel antibiotics

Exclusive By Matthew Herper and Kate Sheridan

Researcher involved in retracted Lancet study has faculty appointment terminated, as details in scandal emerge

Exclusive By Eric Boodman

Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals

Exclusive By Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

Exclusive By Matthew Herper

Inside the NIH’s controversial decision to stop its big remdesivir study

Exclusive By Sharon Begley

Many states are far short of Covid-19 testing levels needed for safe reopening, new analysis shows

Exclusive By Nicholas Florko

Director of U.S. agency key to vaccine development leaves role suddenly amid coronavirus pandemic

Exclusive By Rebecca Robbins

Contract offers unprecedented look at Google deal to obtain patient data from the University of California

Exclusive By Helen Branswell

CDC director: More person-to-person coronavirus infections in U.S. likely, but containment still possible

Exclusive By Erin Brodwin

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

Exclusive By Helen Branswell

Top WHO official says it’s not too late to stop the new coronavirus outbreak

Exclusive By Rebecca Robbins

Medical data startup Syapse cuts 10% of workforce as it prioritizes data analytics and insights

Exclusive By Erin Brodwin

Verily tangos at JPM with a health tech partner — and steps on a few toes